Company: GRCE
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001140361-25-030398
Chunk: 40

Company: Grace Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 8
Chunk 40
---
RL document

      101.SCH

      Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents

      104

      Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

   * Filed or furnished herewith

   † Indicates a management contract or compensatory plan.

   # Filed herewith solely to reflect the name change of the Company from Acasti Pharma Inc. to Grace Therapeutics, Inc.

  38
  

   SIGNATURES

   Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Dated: August 12, 2025

      GRACE THERAPEUTICS, INC.

      By:

      /s/ Prashant Kohli

      Name: Prashant Kohli

      Title: Chief Executive Officer (Principal Executive Officer)

      By:

      /s/ Robert DelAversano

      Name: Robert DelAversano

      Title: Principal Financial Officer (Principal Financial Officer)

   39

http://fasb.org/us-gaap/2025#FairValueAdjustmentOfWarrants
http://fasb.org/us-gaap/2025#FairValueAdjustmentOfWarrants
0001444192
false
2026
Q1
--03-31

    0001444192

    2025-04-01
    2025-06-30

    0001444192

    2025-08-11

    0001444192

    2025-06-30

    0001444192

    2025-03-31

    0001444192

    2024-04-01
    2024-06-30

    0001444192
    
      us-gaap:CommonStockMember

    2025-03-31

    0001444192
    
      us-gaap:AdditionalPaidInCapitalMember

    2025-03-31

    0001444192
    
      us-gaap:AccumulatedOtherComprehensiveIncomeMember

    2025-03-31

    0001444192
    
      us-gaap:RetainedEarningsMember

    2025